 |
|
|
REFERENCES
1.
Mushlin PS, Gelman S: Anesthesia and the liver.
In Barash PG, Cullen BF, Stoelting RK (eds): Clinical
Anesthesia, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 1067–1101.
2.
Gazelle GS, Lee MJ, Muelle PR: Cholangiographic
segmental anatomy of the liver. Radiographics 14(5):1005–1013, 1994.
3.
Heriot AG, Karanjia ND: A review of techniques
for liver resection. Ann R Coll Surg Engl 84(6):371–380, 2002.
4.
Parks RW, Chrysos E, Diamond T: Management of liver
trauma [comment]. Br J Surg 86(9):1121–1135, 1999.
5.
Jones AL: Anatomy of the normal liver. In Zakim
D, Boyer T (eds): Hepatology: a Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 3–32.
6.
Campra JL, Reynolds TB: The hepatic circulation.
In Arias IM, Jakoby WB, Popper H, et al (eds):
The Liver: Biology and Pathobiology, 2nd ed. New York, Raven Press, 1988, pp 911.
7.
Greenway C, Lautt W: Hepatic Circulation: Handbook
of Physiology—The Gastrointestinal System, Motility and Circulation. Bethesda,
American Physiology Society, 1989, pp 1519–1564.
8.
Gelman S, Mushlin PS: Catecholamine induced changes
in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology 100(2):434–439,
2004.
9.
Greenway CV, Innes IR, Scott GD: Pre- and post-sinusoidal
origin of hepatic exudate in anesthetized cats. Can J Physiol Pharmacol 69(12):1914–1916,
1991.
10.
Gelman S: Effects of anesthetics on splanchnic
circulation. In Altura BM, Halvey S (eds): Cardiovascular
Action of Anesthetics and Drugs Used in Anesthesia, 1st ed. Basel, Karger, 1986,
pp 127.
11.
Rappaport AM: Hepatic blood flow: Morphologic
aspects and physiologic regulation. Int Rev Physiol 21:1–63, 1980.
12.
Cooper AJL: Role of the liver in amino acid metabolism.
In Zakim D, Boyer T (eds): Hepatology: A Textbook
of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 563–604.
13.
Zakim D: Metabolism of glucose and fatty acids
by the liver. In Zakim D, Boyer TD (eds): Hepatology:
A Textbook of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 58–92.
14.
Norris CP, Barnes GE, Smith EE, et al: Autoregulation
of superior mesenteric flow in fasted and fed dogs. Am J Physiol 237(2):H174–177,
1979.
15.
Richardson PD, Withrington PG: Liver blood flow.
II. Effects of drugs and hormones on liver blood flow. Gastroenterology 81(2):356–375,
1981.
16.
Richardson PD, Withrington PG: Liver blood flow.
I. Intrinsic and nervous control of liver blood flow. Gastroenterology 81(1):159–173,
1981.
17.
Richardson PD: Physiological regulation of the
hepatic circulation. Fed Proc 41(6):2111–2116, 1982.
18.
Lautt WW: Mechanism and role of intrinsic regulation
of hepatic arterial blood flow: Hepatic arterial buffer response. Am J Physiol
249(5 Pt 1):G549–556, 1985.
19.
Lautt WW: The 1995 Ciba-Geigy Award Lecture.
Intrinsic regulation of hepatic blood flow. Can J Physiol Pharmacol 74(3):223–233,
1996.
20.
Gelman S, Ernst EA: Role of pH, PCO2
,
and O2
content of portal blood in hepatic circulatory autoregulation.
Am J Physiol 233(4):E255–262, 1977.
21.
Jakob SM: Splanchnic blood flow in low-flow states.
Anesth Analg 96(4):1129–1138, 2003.
22.
Jakob SM: Clinical review: Splanchnic ischaemia
[comment]. Crit Care 6(4):306–312, 2002.
23.
Carneiro JJ, Donald DE: Change in liver blood
flow and blood content in dogs during direct and reflex alteration of hepatic sympathetic
nerve activity. Circ Res 40(2):150–158, 1977.
24.
Rappaport AM, Schneiderman JH: The function of
the hepatic artery. Rev Physiol Biochem Pharmacol 76:129–175, 1976.
25.
Richardson PD, Withrington PG: The role of beta-adrenoceptors
in the responses of the hepatic arterial vascular bed of the dog to phenylephrine,
isoprenaline, noradrenaline and adrenaline. Br J Pharmacol 60(2):239–249,
1977.
26.
Richardson PD, Withrington PG: Glucagon inhibition
of hepatic arterial responses to hepatic nerve stimulation. Am J Physiol 233(6):H647–654,
1977.
27.
Cohen MM, Sitar DS, McNeill JR, et al: Vasopressin
and angiotensin on resistance vessels of spleen, intestine, and liver. Am J Physiol
218(6):1704–1706, 1970.
28.
Richardson PD, Withrington PG: The effects of
intra-arterial and intraportal injections of vasopressin on the simultaneously perfused
hepatic arterial and portal venous vascular beds of the dog. Circ Res 43(4):496–503,
1978.
29.
Jalan R, Hayes PC: Hepatic encephalopathy and
ascites. Lancet 350(9087):1309–1315, 1997; see comments.
30.
Friedman LS, Martin P, Munoz SJ: Liver function
tests and the objective evaluation of the patient with liver disease. In
Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 791–832.
31.
Rothschild MA, Oratz M, Schreiber SS: Albumin
synthesis. Int Rev Physiol 21:249–274, 1980.
32.
Rothschild MA, Oratz M, Schreiber SS: Albumin
synthesis. 1. N Engl J Med 286(14):748–757, 1972.
33.
Rothschild MA, Oratz M, Schreiber SS: Albumin
synthesis (second of two parts), N Engl J Med 286(15):816–821, 1972.
34.
Kirsch RE, Saunders SJ, Frith L, et al: Plasma
amino acid concentration and the regulation of albumin synthesis, Am J Clin Nutr
22(12):1559–1562, 1969.
35.
Kirsch R, Frith L, Black E, et al: Regulation
of albumin synthesis and catabolism by alteration of dietary protein. Nature 217(128):578–579,
1968.
36.
Kelman L, Saunders SJ, Frith L, et al: Effects
of amino acids and hormones on the fractional catabolic rate of albumin by the isolated
perfused rat liver. J Nutr 102(8):1045–1048, 1972.
37.
Schreiber G, Urban J: The synthesis and secretion
of albumin. Rev Physiol Biochem Pharmacol 82:27–95, 1978.
38.
Seeff LB: Diagnosis, therapy, and prognosis of
viral hepatitis. In Zakim D, Boyer TD (eds): Hepatology:
A Textbook of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 1067–1145.
39.
Kew MC: Hepatic tumors and cysts. In
Feldman M, Friedman LS, Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal
and Liver Disease: Pathophysiology/Diagnosis/Management, 7th ed. Philadelphia,
WB Saunders, 2002, pp 1577–1602.
40.
Moore MC, Burish MJ, Farmer B, et al: Chronic
hepatic artery ligation does not prevent liver from differentiating portal vs. peripheral
glucose delivery. Am J Physiol Endocrinol Metab 285(4):E845–853, 2003.
41.
Gustavson SM, Chu CA, Nishizawa M, et al: Glucagon's
actions are modified by the combination of epinephrine and gluconeogenic precursor
infusion. Am J Physiol Endocrinol Metab 285(3):E534–544, 2003.
42.
Nishizawa M, Moore MC, Shiota M, et al: Effect
of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
Am J Physiol Endocrinol Metab 284(5):E1027–1036, 2003.
43.
Gustavson SM, Chu CA, Nishizawa M, et al: Interaction
of glucagon and epinephrine in the control of hepatic glucose production in the conscious
dog. Am J Physiol Endocrinol Metab 284(4):E695–707, 2003.
44.
Chu CA, Galassetti P, Igawa K, et al: Interaction
of free fatty acids and epinephrine in regulating hepatic glucose production in conscious
dogs. Am J Physiol Endocrinol Metab 284(2):E291–301, 2003.
45.
Cherrington AD, Sindelar D, Edgerton D, et al:
Physiological consequences of phasic insulin release in the normal animal. Diabetes
51(Suppl 1):S103–108, 2002.
46.
Edgerton DS, Cardin S, Pan C, et al: Effects of
insulin deficiency or excess on hepatic gluconeogenic flux during glycogenolytic
inhibition in the conscious dog. Diabetes 51(11):3151–3162, 2002.
47.
Igawa K, Mugavero M, Shiota M, et al: Insulin
sensitively controls the glucagon response to mild hypoglycemia in the dog. Diabetes
51(10):3033–3042, 2002.
48.
Cardin S, Walmsley K, Neal DW, et al: Involvement
of the vagus nerves in the regulation of basal hepatic glucose production in conscious
dogs. Am J Physiol Endocrinol Metab 283(5):E958–964, 2002.
49.
Goldstein RE, Rossetti L, Palmer BA, et al: Effects
of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent
methods in vivo. Am J Physiol Endocrinol Metab 283(5):E946–957, 2002.
50.
Dunning BE, Moore MC, Ikeda T, et al: Portal glucose
infusion exerts an incretin effect associated with changes in pancreatic neural activity
in conscious dogs. Metabolism 51(10):1324–1330, 2002.
51.
Jetton TL, Shiota M, Knobel SM, et al: Substrate-induced
nuclear export and peripheral compartmentalization of hepatic glucokinase correlates
with glycogen deposition [comment]. Int J Exp Diabetes Res 2(3):173–186, 2001.
52.
Satake S, Moore MC, Igawa K, et al: Direct and
indirect effects of insulin on glucose uptake and storage by the liver. Diabetes
51(6):1663–1671, 2002.
53.
Shiota M, Moore MC, Galassetti P, et al: Inclusion
of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial
hyperglycemia and hyperinsulinemia in the conscious dog. Diabetes 51(2):469–478,
2002.
54.
Chu CA, Sherck SM, Igawa K, et al: Effects of
free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs.
[erratum appears in Am J Physiol Endocrinol Metab 2002 Oct;283(4):section E following
table of contents]. Am J Physiol Endocrinol Metab 282(2):E402–411, 2002.
55.
Moore MC, Satake S, Baranowski B, et al: Effect
of hepatic denervation on peripheral insulin sensitivity in conscious dogs. Am J
Physiol Endocrinol Metab 282(2):E286–296, 2002.
56.
Moore MC, Davis SN, Mann SL, et al: Acute fructose
administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes
Care 24(11):1882–1887, 2001.
57.
Edgerton DS, Cardin S, Emshwiller M, et al: Small
increases in insulin inhibit hepatic glucose production solely caused by an effect
on glycogen metabolism. Diabetes 50(8):1872–1882, 2001.
58.
Shiota M, Postic C, Fujimoto Y, et al: Glucokinase
gene locus transgenic mice are resistant to the development of obesity-induced type
2 diabetes. Diabetes 50(3):622–629, 2001.
59.
Cardin S, Jackson PA, Edgerton DS, et al: Effect
of vagal cooling on the counterregulatory response to hypoglycemia induced by a low
dose of insulin in the conscious dog. Diabetes 50(3):558–564, 2001.
60.
Flattem N, Igawa K, Shiota M, et al: Alpha- and
beta-cell responses to small changes in plasma glucose in the conscious dog. Diabetes
50(2):367–375, 2001.
61.
Jackson PA, Cardin S, Coffey CS, et al: Effect
of hepatic denervation on the counterregulatory response to insulin-induced hypoglycemia
in the dog. Am J Physiol Endocrinol Metab 279(6):E1249–1257, 2000.
62.
Moore MC, Hsieh PS, Neal DW, et al: Nonhepatic
response to portal glucose delivery in conscious dogs. Am J Physiol Endocrinol Metab
279(6):E1271–1277, 2000.
63.
Chu CA, Wiernsperger N, Muscato N, et al: The
acute effect of metformin on glucose production in the conscious dog is primarily
attributable to inhibition of glycogenolysis. Metabolism 49(12):1619–1626,
2000.
64.
Moore MC, Cherrington AD, Mann SL, et al: Acute
fructose administration decreases the glycemic response to an oral glucose tolerance
test in normal adults. J Clin Endocrinol Metab 85(12):4515–4519, 2000.
65.
Connolly CC, Holste LC, Aglione LN, et al: Alterations
in basal glucose metabolism during late pregnancy in the conscious dog. Am J Physiol
Endocrinol Metab 279(5):E1166–1177, 2000.
66.
Chu CA, Sindelar DK, Igawa K, et al: The direct
effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors
in the dog. Am J Physiol Endocrinol Metab 279(2):E463–473, 2000.
67.
Hsieh PS, Moore MC, Neal DW, et al: Importance
of the hepatic arterial glucose level in generation of the portal signal in conscious
dogs. Am J Physiol Endocrinol Metab 279(2):E284–292, 2000.
68.
Shiota M, Jackson P, Galassetti P, et al: Combined
intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic
glucose uptake. Am J Physiol Endocrinol Metab 278(3):E544–552, 2000.
69.
Cardin S, Emshwiller M, Jackson PA, et al: Portal
glucose infusion increases hepatic glycogen deposition in conscious unrestrained
rats. J Appl Physiol 87(4):1470–1475, 1999.
70.
Hsieh PS, Moore MC, Marshall B, et al: The head
arterial glucose level is not the reference site for generation of the portal signal
in conscious dogs. Am J Physiol 277(4 Pt 1):E678–684, 1999.
71.
McGuinness OP, Snowden RT, Moran C, et al: Impact
of acute epinephrine removal on hepatic glucose metabolism during stress hormone
infusion. Metabolism 48(7):910–914, 1999.
72.
Galassetti P, Chu CA, Neal DW, et al: A negative
arterial-portal venous glucose gradient increases net hepatic glucose uptake in euglycemic
dogs. Am J Physiol 277(1 Pt 1):E126–134, 1999.
73.
Galassetti P, Coker RH, Lacy DB, et al: Prior
exercise increases net hepatic glucose uptake during a glucose load. Am J Physiol
276(6 Pt 1):E1022–1029, 1999.
74.
Hsieh PS, Moore MC, Neal DW, et al: Rapid reversal
of the effects of the portal signal under hyperinsulinemic conditions in the conscious
dog. Am J Physiol 276(5 Pt 1):E930–937, 1999.
75.
Cherrington AD: Banting Lecture 1997. Control
of glucose uptake and release by the liver in vivo. Diabetes 48(5):1198–1214,
1999.
76.
Nordlie RC, Foster JD, Lange AJ: Regulation of
glucose production by the liver. Annu Rev Nutr 19:379–406, 1999.
77.
Fanelli CG, Pampanelli S, Porcellati F, et al:
Rate of fall of blood glucose and physiological responses of counterregulatory hormones,
clinical symptoms and cognitive function to hypoglycaemia in Type I diabetes mellitus
in the postprandial state. Diabetologia 46(1):53–64, 2003.
78.
Hallsten K, Yki-Jarvinen H, Peltoniemi P, et al:
Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in
obese men. Obes Res 11(2):257–265, 2003.
79.
De Feo P, Pampanelli S, Porcellati F, et al: Adrenaline
vs glucagon in the primacy of glucose counterregulation. Diabetes Nutr Metab 15(5):323–327;
discussion 328, 2002.
80.
Bolli GB: Clinical strategies for controlling
peaks and valleys: Type 1 diabetes. Int J Clin Pract Suppl (129):65–74, 2002.
81.
Owens DR, Zinman B, Bolli GB: Insulins today and
beyond. [erratum appears in Lancet 2001 Oct 20;358(9290):1374]. Lancet 358(9283):739–746,
2001.
82.
Bolli GB, Fanelli CG: Physiology of glucose counterregulation
to hypoglycemia. Endocrinol Metab Clin North Am 28(3):467–493, v, 1999.
83.
Seywert AJ, Tappy L, Gremion G, et al: Effect
of a program of moderate physical activity on mental stress-induced increase in energy
expenditure in obese women. Diabetes Metab 28(3):178–183, 2002.
84.
Tappy L, Cayeux MC, Gillet M, et al: Measurement
of the whole body clearance of infused glycerol as a test of liver function after
major hepatectomy. Clin Physiol Funct Imaging 22(4):266–270, 2002.
85.
Minehira K, Tappy L, Chiolero R, et al: Fractional
hepatic de novo lipogenesis in healthy subjects during near-continuous oral nutrition
and bed rest: A comparison with published data in artificially fed, critically ill
patients. Clin Nutr 21(4):345–350, 2002.
86.
Dirlewanger M, Schneiter P, Jequier E, et al:
Effects of fructose on hepatic glucose metabolism in humans. Am J Physiol Endocrinol
Metab 279(4):E907–911, 2000.
87.
Seematter G, Battilana P, Tappy L: Effects of
dexamethasone on the metabolic responses to mental stress in humans. Clin Physiol
Funct Imaging 22(2):139–144, 2002.
88.
Seematter G, Dirlewanger M, Rey V, et al: Metabolic
effects of mental stress during over- and underfeeding in healthy women. Obes Res
10(1):49–55, 2002.
89.
Tappy L, Minehira K: New data and new concepts
on the role of the liver in glucose homeostasis. Curr Opin Clin Nutr Metab Care
4(4):273–277, 2001.
90.
Tirone TA, Brunicardi FC: Overview of glucose
regulation. World J Surg 25(4):461–467, 2001.
91.
Stolz A: Liver physiology and metabolic function.
In Feldman M, Friedman LS, Sleisenger MH (eds):
Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management,
7th ed. Philadelphia, WB Saunders, 2002, pp 1202–1226.
92.
Riou JP, Claus TH, Pilkis SJ: Stimulation of glucagon
of in vivo phosphorylation of rat hepatic pyruvate kinase. J Biol Chem 253(3):656–659,
1978.
93.
Sharma RJ, Rodrigues LM, Whitton PD, et al: Control
mechanisms in the acceleration of hepatic glycogen degradation during hypoxia. Biochim
Biophys Acta 630(3):414–424, 1980.
94.
Lewis GF: Fatty acid regulation of very low density
lipoprotein production. Curr Opin Lipidol 8(3):146–153, 1997.
95.
Lewis GF, Vranic M, Harley P, et al: Fatty acids
mediate the acute extrahepatic effects of insulin on hepatic glucose production in
humans. Diabetes 46(7):1111–1119, 1997.
96.
Lamarche B, Lewis GF: Atherosclerosis prevention
for the next decade: Risk assessment beyond low density lipoprotein cholesterol.
Can J Cardiol 14(6):841–851, 1998.
97.
Lewis GF, Vranic M, Giacca, A: Role of free fatty
acids and glucagon in the peripheral effect of insulin on glucose production in humans.
Am J Physiol 275(1 Pt 1):E177–186, 1998.
98.
Adeli K, Taghibiglou C, Van Iderstine SC, et al:
Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.
Trends Cardiovasc Med 11(5):170–176, 2001.
99.
Rashid S, Shi ZQ, Niwa M, et al: Beta-blockade,
but not normoglycemia or hyperinsulinemia, markedly diminishes stress-induced hyperglycemia
in diabetic dogs. Diabetes 49(2):253–262, 2000.
100.
Lewis GF: Lipid metabolism. Curr Opin Lipidol
13(1):97–99, 2002.
101.
Lewis GF, Carpentier A, Adeli K, et al: Disordered
fat storage and mobilization in the pathogenesis of insulin resistance and type 2
diabetes. Endocr Rev 23(2):201–229, 2002.
102.
Carpentier A, Taghibiglou C, Leung N, et al:
Ameliorated hepatic insulin resistance is associated with normalization of microsomal
triglyceride transfer protein expression and reduction in very low density lipoprotein
assembly and secretion in the fructose-fed hamster. J Biol Chem 277(32):28795–28802,
2002.
103.
Taghibiglou C, Rashid-Kolvear F, Van Iderstine
SC, et al: Hepatic very low density lipoprotein-ApoB overproduction is associated
with attenuated hepatic insulin signaling and overexpression of protein-tyrosine
phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem
277(1):793–803, 2002.
104.
Lam TK, Carpentier A, Lewis GF, et al: Mechanisms
of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol
Endocrinol Metab 284(5):E863–873, 2003.
105.
Carpentier A, Zinman B, Leung N, et al: Free
fatty acid-mediated impairment of glucose-stimulated insulin secretion in nondiabetic
Oji-Cree individuals from the Sandy Lake community of Ontario, Canada: A population
at very high risk for developing type 2 diabetes. Diabetes 52(6):1485–1495,
2003.
106.
Lutz TA, Tschudy S, Mollet A, et al: Dopamine
D(2) receptors mediate amylin's acute satiety effect. Am J Physiol Regul Integr
Comp Physiol 280(6):R1697–1703, 2001.
107.
Scharrer E: Control of food intake by fatty acid
oxidation and ketogenesis. Nutrition 15(9):704–714, 1999.
108.
Chan L, Jackson RL, O'Malley BW, et al: Synthesis
of very low density lipoproteins in the cockerel. Effects of estrogen. J Clin Invest
58(2):368–379, 1976.
109.
Miles JM, Haymond MW, Gerich JE: Suppression
of glucose production and stimulation of insulin secretion by physiological concentrations
of ketone bodies in man. J Clin Endocrinol Metab 52(1):34–37, 1981.
110.
Fitz JG: Cellular mechanisms of bile secretion.
In Zakim D, Boyer TD (eds): Hepatology: A Textbook
of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 362–376.
111.
Dawson PA: Bile secretion and the enterohepatic
circulation of bile acids. In Feldman M, Friedman
LS, Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal and Liver
Disease: Pathophysiology/Diagnosis/Management, 7th ed. St. Louis, WB Saunders,
2002, pp 1051–1064.
112.
Leonis MA, Balistreri WF: Inherited metabolic
disorders of the liver. In Feldman M, Friedman LS,
Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal and Liver Disease:
Pathophysiology/Diagnosis/Management, 7th ed. Philadelphia, WB Saunders, 2002,
pp 1240–1260.
113.
Vlahcevic ZR, Heuman DM, Hylemon PB: Physiology
and pathophysiology of enterohepatic circulation of bile acids. In
Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 376–417.
114.
Radnay PA, Duncalf D, Novakovic M, et al: Common
bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol, and
naloxone. Anesth Analg 63(4):441–444, 1984.
115.
Fitz JG: Hepatic encephalopathy, hepatopulmonary
syndromes, hepatorenal syndrome, coagulopathy, and endocrine complications of liver
disease. In Feldman M, Friedman LS, Sleisenger MH
(eds): Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management,
7th ed. St. Louis, WB Saunders, 2002, pp 1543–1567.
116.
Nelsestuen GL, Shah AM, Harvey SB: Vitamin K-dependent
proteins. Vitam Horm 58:355–389, 2000.
117.
Sunnerhagen M, Drakenberg T, Forsen S, et al:
Effect of Ca2+
on the structure of vitamin K-dependent coagulation factors.
Haemostasis 26(Suppl 1):45–53, 1996.
118.
Berkner KL: The vitamin K-dependent carboxylase.
J Nutr 130(8):1877–1880, 2000.
119.
Dowd P, Ham SW, Naganathan S, et al: The mechanism
of action of vitamin K. Annu Rev Nutr 15:419–440, 1995.
120.
Furie BC, Furie, B: Structure and mechanism of
action of the vitamin K-dependent gamma-glutamyl carboxylase: recent advances from
mutagenesis studies. Thromb Haemost 78(1):595–598, 1997.
121.
Suttie JW: Synthesis of vitamin K-dependent proteins.
FASEB J 7(5):445–452, 1993.
122.
Sugiura I, Furie B, Walsh CT, et al: Propeptide
and glutamate-containing substrates bound to the vitamin K-dependent carboxylase
convert its vitamin K epoxidase function from an inactive to an active state. Proc
Natl Acad Sci U S A 94(17):9069–9074, 1997.
123.
Fujita H: Molecular mechanism of heme biosynthesis.
Tohoku J Exp Med 183(2):83–99, 1997.
124.
Ponka P: Cell biology of heme. Am J Med Sci
318(4):241–256, 1999.
125.
Ferreira GC, Gong J: 5-Aminolevulinate synthase
and the first step of heme biosynthesis. J Bioenerg Biomembr 27(2):151–159,
1995.
126.
Sassa S: Regulation of the genes for heme pathway
enzymes in erythroid and in non-erythroid cells. Int J Cell Cloning 8(1):10–26,
1990.
127.
Daniell WE, Stockbridge HL, Labbe RF, et al:
Environmental chemical exposures and disturbances of heme synthesis. Environ Health
Perspect 105(Suppl 1):37–53, 1997.
128.
Anderson KE: The porphyrias. In
Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 417–465.
129.
Jensen NF, Fiddler DS, Striepe V: Anesthetic
considerations in porphyrias[comment]. Anesth Analg 80(3):591–599, 1995.
130.
Ashley EM: Anaesthesia for porphyria. Br J Hosp
Med 56(1):37–42, 1996.
131.
James MF, Hift RJ: Porphyrias. Br J Anaesth
85(1):143–153, 2000.
132.
Baker SD, Taylor B: Anaesthesia is also risky
in patients with porphyria [comment]. BMJ 321(7267):1023, 2000.
133.
Marks GS, McCluskey SA, Mackie JE, et al: Disruption
of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P-450.
FASEB J 2(12):2774–2783, 1988.
134.
Marks GS: Exposure to toxic agents: The heme
biosynthetic pathway and hemoproteins as indicator. Crit Rev Toxicol 15(2):151–179,
1985.
135.
Shibahara S, Kitamuro T, Takahashi K: Heme degradation
and human disease: Diversity is the soul of life. Antioxid Redox Signal 4(4):593–602,
2002.
136.
Schmid R: Bilirubin metabolism: State of the
art. Gastroenterology 74(6):1307–1312, 1978.
137.
Moller S, Becker U: Insulin-like growth factor
1 and growth hormone in chronic liver disease. Dig Dis 10(4):239–248, 1992.
138.
Rojdmark S, Bloom G, Chou MC, et al: Hepatic
extraction of exogenous insulin and glucagon in the dog. Endocrinology 102(3):806–813,
1978.
139.
Rojdmark S, Bloom G, Chou MC, et al: Hepatic
insulin and glucagon extraction after their augmented secretion in dogs. Am J Physiol
235(1):E88–96, 1978.
140.
Laskin DL: Nonparenchymal cells and hepatotoxicity.
Semin Liver Dis 10(4):293–304, 1990.
141.
Dhainaut JF, Marin N, Mignon A, et al: Hepatic
response to sepsis: Interaction between coagulation and inflammatory processes.
Crit Care Med 29 (7 Suppl):S42–47, 2001.
142.
Bosch-Morell F, Flohe L, Marin N, et al: 4-Hydroxynonenal
inhibits glutathione peroxidase: Protection by glutathione. Free Radic Biol Med
26(11–12):1383–1387, 1999.
143.
Lemasters JJ: V. Necrapoptosis and the mitochondrial
permeability transition: Shared pathways to necrosis and apoptosis. Am J Physiol
276(1 Pt 1):G1–6, 1999.
144.
Bautista AP, Spitzer JJ: Role of Kupffer cells
in the ethanol-induced oxidative stress in the liver. Front Biosci 4:D589–595,
1999.
145.
Bailey SM, Reinke LA: Antioxidants and gadolinium
chloride attenuate hepatic parenchymal and endothelial cell injury induced by low
flow ischemia and reperfusion in perfused rat livers. Free Radic Res 32(6):497–506,
2000.
146.
DeLeve LD, McCuskey RS, Wang X, et al: Characterization
of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 29(6):1779–1791,
1999.
147.
Farrell GC: Liver disease caused by drugs, anesthetics,
and toxins. In Feldman M, Friedman LS, Sleisenger
MH (eds): Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management,
7th ed. St. Louis, WB Saunders, 2002, pp 1403–1447.
148.
Vessey DA: Metabolism of xenobiotics by the human
liver. In Zakim D, Boyer TD (eds): Hepatology:
A Textbook of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 257–306.
149.
Estabrook R: An introduction to the cytochrome
P450s. Mol Aspects Med 20(1–2):5–12, 13–137, 1999.
150.
Murray M: Mechanisms and significance of inhibitory
drug interactions involving cytochrome P450 enzymes [review]. Int J Mol Med 3(3):227–238,
1999.
